Standardization of training is possible! Introducing a simulator for endovascular treatment. Limited-time 60% OFF campaign is currently underway.
"AngioVision" is an endovascular treatment simulator that allows training without causing invasiveness to actual patients, enabling users to make mistakes in a controlled and safe environment. It features a virtual model of the patient's arterial system based on actual patient images and 3D technology. The software of this product offers a wide range of training, tools, and functions. It is designed not only for instructors but also as an effective educational base for behavior training in rules and knowledge to safely perform endovascular procedures. [Features] ■ Can be installed in various training rooms ■ Standardization of training is possible ■ Haptic feedback - Suitable for training in radiology, cardiology, and neurosurgery ■ Capable of operating actual endovascular treatment devices ■ Can handle multiple virtual endovascular treatment devices *For more details, please refer to the PDF materials or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 ■ Abundant educational content ■ Easy-to-use touch panel ■ Customizable educational courses ■ High-precision motion detection ■ Capable of simultaneous operation of three devices ■ Capable of both translational and rotational movement, allowing for high degrees of freedom in operation *For more details, please refer to the PDF materials or feel free to contact us.
Price range
P6
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（2）
Download All Catalogs
Company information
Danaform Inc. is a company established in 1998, based on the RIKEN Venture System of the National Research and Development Agency RIKEN, with Yoshihide Hayasaki from RIKEN (who has been the representative director of Danaform Inc. since 2021) at its core. The company is actively engaged in gene analysis and genetic testing, focusing on technologies co-developed by Danaform and RIKEN, including contract analysis using next-generation sequencers such as CAGE-seq and RNA-seq, the sale of fluorescent reagents Eprobe capable of SNP detection, and the sale of various clones, boasting a significant inventory. Moving forward, we aim to refine our proprietary technologies and strive for higher quality research and manufacturing as experts in the field of genetics, with the hope of contributing to people's health.
